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Abstract
Background: Cerebral ischemia involves a series of reactions which ultimately influence the final
volume of a brain infarction. We hypothesize that polymorphisms in genes encoding proteins
involved in these reactions could act as modifiers of the cerebral response to ischemia and impact
the resultant stroke volume. The final volume of a cerebral infarct is important as it correlates with
the morbidity and mortality associated with non-lacunar ischemic strokes.
Methods:  The proteins encoded by the methylenetetrahydrofolate reductase (MTHFR) and
glutathione S-transferase omega-1 (GSTO-1) genes are, through oxidative mechanisms, key
participants in the cerebral response to ischemia. On the basis of these biological activities, they
were selected as candidate genes for further investigation. We analyzed the C677T polymorphism
in the MTHFR gene and the C419A polymorphism in the GSTO-1 gene in 128 patients with non-
lacunar ischemic strokes.
Results: We found no significant association of either the MTHFR (p = 0.72) or GSTO-1 (p = 0.58)
polymorphisms with cerebral infarct volume.
Conclusion: Our study shows no major gene effect of either the MTHFR or GSTO-1 genes as a
modifier of ischemic stroke volume. However, given the relatively small sample size, a minor gene
effect is not excluded by this investigation.
Background
In the United States, after cardiovascular disease and can-
cer, stroke is the third leading cause of death. However, it
is the leading cause of morbidity resulting in about 4 mil-
lion stroke survivors each year [1]. Although there are epi-
demiological differences in various ethnic groups, the
majority of these strokes are ischemic rather than hemor-
rhagic in nature. There are a number of well established
risk factors for the development of ischemic stroke includ-
ing diabetes mellitus, atrial fibrillation, hypertension and
age [2]. Once an ischemic stroke occurs, in spite of intense
research efforts, little progress has been made in the dis-
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covery or development of effective neuroprotective
agents.
While there are recent research efforts investigating sus-
ceptibility genes for ischemic stroke, there are few investi-
gations of the genetics of the cerebral response to ischemia
[3,4]. Studies of induced strokes in transgenic animals
indicate that manipulation of certain genes can influence
the resultant volume [5,6]. We hypothesize that there is
variability in the cerebral response to ischemia that is
mediated by polymorphisms in genes encoding proteins
which participate in this response. Polymorphisms in
these genes could enhance or diminish endogenous neu-
roprotective mechanisms and ultimately impact the vol-
ume of an ischemic stroke. This has clinical significance
because, in general, the volume of a stroke correlates with
severity and the resultant degree of disability of the
patient [7,8].
It has been established that cerebral ischemic injury
results in a core of necrotic tissue surrounded by a penum-
bra of tissue in which neurons are functionally inactive
but still potentially viable [9]. The development of this
ischemic penumbra is limited in time by a cascade of reac-
tions in response to the initial ischemia followed by sub-
sequent reperfusion. Reperfusion occurring shortly after
ischemia reduces infarct volume, but at a later period may
exacerbate ischemic injury [10]. It has been suggested that
reperfusion increases reactive oxygen species (ROS) pro-
duction which can have further deleterious consequences.
Neuronal cell exposure to these ROS, which include nitric
oxide, superoxide ions and hydroxyl radicals, can result in
oxidative deoxyribonucleic acid (DNA) damage [11-14].
Methylenetetrahydrofolate reductase (MTHFR) and Glu-
tathione S-transferase omega-1(GSTO-1) are two genes
that are key participants in the metabolic pathways regu-
lating oxidative stress in the brain (Fig 1). The C677T pol-
ymorphism (NCBI SNP cluster ID rs# 1801133) in
MTHFR gene results in an alanine-to-valine (A222V) sub-
stitution which in turn causes a reduction in enzyme activ-
ity and subsequent elevation of plasma homocysteine
[15,16]. Hyperhomocysteinemia (HHcy) has been
reported as an independent risk factor for stroke but may
also influence ischemic stroke volume. A study of the cer-
ebral volume and induced stroke following middle cere-
bral artery occlusion in mice showed that HHcy was
associated with increased oxidative damage and larger
ischemic lesion [17-19]. The homocysteine (Hcy)
dependent trans-sulfuration pathway is responsible for
maintenance of the intracellular glutathione pool and reg-
ulation of this pathway under oxidative stress (Fig 1).
GSTO-1 is member of Phase II enzymes that catalyze glu-
tathione-dependent antioxidant pathways (Fig 1). Fur-
thermore GSTO-1 modulates rynodyne receptors thereby
protecting cells against Ca2+ induced apoptosis and inhi-
bition of the posttranslational processing of pro-inflam-
matory cytokine interleukin-1β [20,21]. The C419A
(NCBI SNP cluster ID, rs 4925) polymorphism in GSTO-
1 gene has been reported to be involved in stroke [22].
The C419A polymorphism results in amino acid altera-
tion alanine-to-aspartate; this change in the protein
sequence reduces enzyme activity and therefore could
influence tissue susceptibility to oxidative stress [23].
Given the key roles of the products of these two genes in
the cerebral response to ischemia, they are candidate
genes which warrant further investigation. We hypothe-
sized that the MTHFR C677T and GSTO-1 C419A poly-
morphisms may modify the response of the brain to
cerebral ischemia and ultimately impact the final stroke
volume. To test our hypothesis we studied the relation-
ship of these polymorphisms with infarct volume meas-
ured in patients who have suffered an ischemic stroke.
Methods
Human subjects
We studied 128 patients admitted to the stroke unit at
John F. Kennedy Medical Center, Edison, New Jersey with
non-lacunar ischemic infarcts. The strokes were catego-
rized according to the Trial of ORG 10172 in Acute Stroke
Treatment (TOAST) [24]. Among these patients, applying
the TOAST classification, the etiology of the non-lacunar
ischemic strokes included 37 large artery atherothrombo-
sis, 37 cardioembolic, 49 unknown and 5 others. In the
majority of patients (79%), diffusion-weighted magnetic
resonance imaging scans were available for review; alter-
natively, cerebral computed tomography scans (21%)
were used to measure stroke volume. The stroke volume
was obtained by averaging the calculated values from
direct measurements of the cerebral images by two exam-
iners as previously described [25]. Informed consents
were obtained from the patients or their proxies and study
was conducted according to protocols and methods
approved by the local Institutional Review Board.
Genotyping
Genomic DNA was isolated from blood samples (Pure-
gene Systems, Gentra). The MTHFR polymorphisms were
genotyped as previously described [15]. Briefly, the
primer pairs used were F: 5'-TGAAGGAGAAGGTGTCT-
GCGGGA-3' and R: 5'-AGGACGGTGCGGTGAGAGTG-3'.
The C677T polymorphism creates a restriction site for
Hinf I, so the digestion of the polymerase chain reaction
(PCR) products of the mutant allele generates two frag-
ments (175 and 23 bp). The digested products were
resolved by gel electrophoresis (6% polyacrylamide gel)
and the allele frequency was obtained by direct gene
counting. The genotypes obtained with this method were
confirmed by direct sequencing.BMC Neurology 2009, 9:37 http://www.biomedcentral.com/1471-2377/9/37
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The GSTO-1 polymorphism was detected after PCR ampli-
cation using following primer pairs F: 5'-TGTCTAGGT-
GCCATCCTTGGT-3' and R: 5'-AAGTGACTTGGAAAGTG
GGAA-3'. PCR was carried out in a final volume of 50 μl
with 40 ng of DNA, 600 μM dNTP and 2.5 U Amplitaq
gold polymerase. Thermal cycling consisted of initial acti-
vation (95°C for 7 min) followed by 35 cycles of denatur-
ation (95°C, 30 s), annealing (56°C, 30 s), and extension
(72°C, 30 s) and a final extention at 72°C for 7 min. PCR
products were digested with restriction enzyme Cac8I at
37°C overnight and the digested products were resolved
by gel electrophoresis (6% polyacrylamide gel). The diges-
tion generates two fragments (147 bp and 60 bp) corre-
sponding to C (restriction site present) and a single 207
bp product corresponding to the A allele (restriction site
absent). The allele frequency was obtained by direct gene
counting. The genotypes obtained with this method were
confirmed by direct sequencing.
Results
The clinical and demographic data of the study group is
presented in table 1. The genotypes of the MTHFR C677T
and  GSTO-1  C419A polymorphisms are presented in
table 2. The observed numbers of each genotype was com-
pared with those expected under Hardy-Weinberg equilib-
rium (HWE) by using a web-based program http://
ihg.gsf.de/cgi-bin/hw/hwa1.pl. No significant deviation
from HWE was observed. The mean Hcy levels corre-
sponding to each genotype is presented in the table 3.
Although the mean Hcy level is higher in the group with
MTHFR TT genotype, it is not statistically significant. To
detect the effect of the MTHFR C677T and GSTO-1 C419A
polymorphisms on stroke volume ANOVA and general-
ized linear model analysis was done. The mean stroke vol-
ume was 71.37 cm3  (SD 90.1 cm3). There was no
significant influence of the MTHFR (p = 0.72) or GSTO-1
(p = 0.58) polymorphisms on the stroke volume. The
analysis was also performed for Caucasian population
The metabolic pathways regulating oxidative stress Figure 1
The metabolic pathways regulating oxidative stress. Abbreviations: MTHFR- Methylenetetrahydrofolate reductase, 
THF- tetrahydro folate, Hcy- Homocysteine, SAM- S-Adenosyl methionine, eNOS-endothelial nitric oxide synthase, iNOS-
inducible nitric oxide synthase, ADMA- asymmetric dimethylarginine, NO- nitric oxide, O2
- – superoxide radical, ONOO- per-
oxinitrite, H2O2-hydrogen peroxide, NADPH – nicotinamide adenine dinucleotide phosphate, GSTO-1- Glutathione S-trans-
ferase omega-1, GSSG -glutathione disulfide, ROOH- reduced hydroperoxides, ROH- alcohol, H2O- water.BMC Neurology 2009, 9:37 http://www.biomedcentral.com/1471-2377/9/37
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alone which represented 67.2% of the study population.
However no significant effect of either MTHFR (p = 0.41)
or GSTO-1 (p = 0.83) polymorphisms on the size of stroke
was detected.
Discussion
Our analysis did not show a major gene effect of either the
MTHFR C677T polymorphism or GSTO-1 C419A poly-
morphism on the volume of the ischemic infarct. How-
ever, minor genetic effects are not excluded by this study.
It is possible that such minor gene effects may be additive
and particular combinations of polymorphisms from dif-
ferent genes may confer neuroprotection. These minor
gene effects could be detected by studying a much larger
sample size.
In addition to investigating genes involved in the
response of the brain following ischemia, there are other
variables that could confound the analysis. For example,
due to our relatively small sample size we did not separate
and analyze the volumes of strokes occurring in a particu-
lar vascular distribution. To enhance the detection of
minor gene effects, future studies could focus only upon
middle cerebral artery stroke. In this study, again due to
small sample size, we did not limit our analysis to those
strokes of a particular etiology but rather focused upon
the entire group. There may to be biological/genetic differ-
ences in the cerebral response to ischemia in cardioem-
bolic stroke compared with large artery atherosclerosis.
Conclusion
In spite of the negative results, our study demonstrates the
feasibility of studying the potential role of genes which
participate in the cerebral response to ischemia and ulti-
mately influence stroke volume. Many of the difficulties
of any such investigation can be overcome by studying a
larger sample size of patients. These studies could provide
insight into endogenous neuroprotective mechanisms
and facilitate the development of more effective therapies.
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Table 3: Genotype and homocysteine data
Genotype N Mean plasma homocysteine (μmol/L)
MTHFR C677T CC 38 10.7
CT 44 10.8
TT 14 11.7
GSTO-1 C419A CC 43 10.7
AC 40 10.7
AA 12 10.3
Table 1: Patient characteristics. 
Demographic factors
Female n (%) 69 (52.4)
Age, y mean (S.Da) 70.7 (13.1)
Ethnicity n (%)
Caucasians 86 (67.2)
African Americans 9 (7.0)
Hispanics 13 (10.2)
Othersb 20 (15.6)
Co morbiditiesc n (%)
Hypertension 105 (82.0)
Diabetes 55 (43.0)
Atrial fibrillation 37 (28.9)
Carotid stenosis = 70% 41 (32.3)
TOAST Classificationd n (%)




The clinical and demographic data of the study group.
a S.D = Standard deviation.
b Include Asians and other ethnic groups.
c Other factors studied include Coronary artery disease, Peripheral 
vascular disease, Lipid profile, Homocysteine levels.
d TOAST = Trial of Org 10172 in Acute Stroke Treatment.
e Include stroke of undetermined etiology or those due to two or 
more causes.
Table 2: Genotype and stroke volume data.
Genotype N Mean stroke volume (cm3)
C677T CC 49 59.5
CT 60 84.6
TT 18 61.5
C419A CC 55 72.7
AC 54 74.0
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